Jasper Therapeutics, Inc. - 8-K Filing
Jasper Therapeutics announced on June 1, 2026, that its Board of Directors has initiated a strategic review to explore alternatives aimed at maximizing shareholder value. Options under consideration include asset sales, licensing deals, collaborations, mergers or acquisitions, and an orderly wind-down of operations. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $JSPR